Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?

This publication has 14 references indexed in Scilit:

• Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
  Journal of Clinical Oncology, 2007
• KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
  Clinical Cancer Research, 2007
• Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells in Human Renal Cell Carcinoma Is a Primary Target for Therapy by Tyrosine Kinase Inhibitors
  Neoplasia, 2006
• KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
  Cancer Research, 2006
• Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model
  Cancer Research, 2005
• The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
  Clinical Cancer Research, 2005
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  PLoS Medicine, 2005
• Frequency of K-ras Mutations in Pancreatic Intraductal Neoplasias Associated with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Meta-Analysis
  Neoplasia, 2005
• Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human Carcinomas
  The American Journal of Pathology, 2002
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000